
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals Inc is positioned for significant revenue growth, with projections indicating that revenues associated with the Khindivi product will escalate to a peak of $28 million by 2030, up from just $3 million in 2025. The recent approval of Khindivi has led to an increase in the probability of its launch to 100% and an anticipated market penetration of 60%, highlighting a strong momentum in commercial execution. These factors, combined with a favorable timeline for market entry, suggest that 2025 could mark an important inflection point in the company’s revenue trajectory.
Bears say
Eton Pharmaceuticals's financial outlook reflects concerns regarding its current valuation, supported by an 11% discount rate and a modest 2% terminal growth rate, which suggest limited growth potential. The adjustments to the 12-month price target, increasing from $33 to $35 per diluted share, indicate a cautious optimism but still suggest underlying challenges that may prevent significant upward momentum. These factors collectively contribute to a negative sentiment surrounding the stock, highlighting the need for improved performance and market confidence to justify the current valuation.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares